This article is sixth in a Deal Screening Mastery series for emerging investors who want to build LP confidence and for early‑stage companies trying to find the right investor fit. In the fifth article, “‘Why Now?‘ Is an Investment Question, Not a Marketing Slide,” I showed you how to turn the inevitable slide into a functional investment question for healthcare and life sciences deals.
Every investor says they care about regulatory risk and reimbursement risk. Far fewer know how to screen for them well. That gap matters because some of the most expensive mistakes in healthcare investing are not failures of science, charisma, or market size. They are failures of path design. A company can have a talented team, a legitimate unmet need, and a technically impressive product and still be fundamentally unfinanceable if its regulatory route is fuzzy, its reimbursement logic is imaginary, or its milestones do not line up with the capital being raised.
This is one reason early healthcare deal screening can feel so slippery. Founders often treat regulatory and reimbursement as downstream execution details. Investors often pretend they can defer the hard questions until diligence, after they have already invested time, attention, and increasingly, internal conviction. But path risk is not a late-stage issue. In many health and life sciences deals, it is integral to the product itself.
That is the frame for this article. Regulatory and reimbursement readiness is not about whether a company has solved every downstream question. It is about whether the company has a coherent, stage-appropriate, fundable path through systems that do not care how compelling the pitch sounds. As a screen, this lens is less about encyclopedic expertise than about pattern recognition: can this founder explain how the product moves from promising idea to approved, paid-for, repeatably adopted offering without dissolving into generalities? In the last article, the focus was on “Why now?” and the difference between real timing edges and trend-chasing. This article is the natural sequel. A strong “why now” may tell you the wind is at the company’s back. Regulatory and reimbursement readiness tell you whether the founder is using a realistic map for the journey or simply assuming they can use roadside signs as they go.
It helps to define what we mean by “readiness.” At screening stage, readiness does not mean the company has complete regulatory certainty, final coding, locked coverage, or a polished market-access dossier. In many cases, especially at seed, that would be unrealistic. It does mean the company understands the governing logic of its path well enough to make intelligent decisions about product design, claims, trial design, commercial sequencing, and capital planning. [1]
Regulatory readiness means the founder can articulate the likely pathway, the major alternatives, the key decision points, and the main risks without sounding like they are reading from a consultant’s memo they barely understood. Reimbursement readiness means the founder can identify the economic buyer, the likely payment mechanism, and the financial reason someone will care, with enough specificity to survive follow-up questions. Both are really tests of operating literacy.
This distinction matters because founders often confuse the presence of advisors with readiness. A slide that says “Former FDA official” or “Top reimbursement consultant” may be reassuring, but it is not the same thing as a management team that has internalized the implications of those conversations. When investors are screening deals, do not just want to know if smart people are somewhere in the orbit. They want to know whether the company’s choices already reflect a level of understanding consistent with team + advisor expertise.
In practice, regulatory and reimbursement readiness usually exists at one of three levels. At the bottom, there is no readiness at all: vague labels, magical timelines, fuzzy ownership of the payment decision, and an almost devotional confidence that good clinical data will cause the rest of the system to sort itself out. This level is often noticeable by timelines that jump straight from “clinical” to “revenue” with no intervening infrastructure. In the middle is hypothesis-level readiness: the founder can describe a plausible route, identify known unknowns, and explain what must be learned with this next tranche of capital. At the high end is execution-level readiness: the pathway is not just coherent but increasingly de-risked by formal feedback, pilot structures, code strategy, payer conversations, or prior precedent. For deal screening, that middle category matters most. The goal is not to back only companies that have fully derisked the path. Rather, investors want to back companies that know what their path is.
One of the cleanest ways to identify a weak healthcare deal is to ask a deceptively simple question, “What do the regulators think you are?” This sounds basic, but it is astonishing how often the answer is evasive. Some founders hide behind category ambiguity because they think flexibility is strategically valuable. Others genuinely have not done the work. They describe themselves as a platform, or an AI layer, or an enabling technology, and hope that abstraction exempts them from the burden of a path. It does not. The point of a screening conversation is not to master every detail of every possible framework. It is to understand whether the company’s intended use, claims, risk profile, and route to market align with the regulatory route they are implying. Advanced diagnostics sit where scientific novelty, clinical workflow, and coverage policy collide; success depends not just on analytical and clinical validity, but on generating evidence and economics that simultaneously satisfy regulators, payers, and ordering clinicians.
A founder who understands the path usually sounds different in three ways. First, they can name the route with specificity. That may mean a particular device pathway, a laboratory strategy, a software classification, a benefit-category issue, or a jurisdictional sequence rather than a generic “FDA first, Europe later.” Precision is usually a sign of thought. Second, they can explain why that route fits the product’s actual intended use. This is often where weaker teams unravel. They often speak about the most flattering or fastest-sounding pathway, not the one their claims would logically trigger. Once you ask what evidence that pathway requires, or how their claims would need to be tightened to stay within that route, the answer gets foggy. Third, they can connect the regulatory path to financing logic. The milestone they are raising against should make sense. A company should be able to say, in plain English, that this round gets them to a pre-submission meeting, a pivotal design decision, a validation package, a first clearance, a laboratory milestone, or some other decision point that materially changes the next round’s risk profile. If the capital raise and the regulatory milestones do not line up, that is not just a planning problem. It is a financing problem. This is one reason overconfidence is such a poor signal in healthcare investing. The best founders are rarely casual about regulation. They usually know where the uncertainty lives. They can tell you the top one or two issues that worry them and how they plan to reduce those risks. When a founder says, “We do not anticipate major regulatory challenges,” the most generous interpretation is that they do not yet know enough to be worried.
If regulatory readiness asks whether the company can get through the front door, reimbursement readiness asks whether anyone meaningful will pay to keep it inside the building. This is where many early companies drift into fantasy. They conflate price with payment. They say a product saves money, improves outcomes, or addresses an expensive disease area, and assume the system will naturally reward those virtues with coverage and payment. Healthcare does not work that way. Plenty of products get through the door only to be evicted by misaligned incentives. A reimbursement story becomes credible when it answers three plain questions. Who is the economic buyer? What is the likely payment mechanism? Why does that buyer care in financial, not rhetorical, terms?
For advanced diagnostics, investors should listen for whether the founder separates coding, coverage, and payment instead of treating ‘reimbursement’ as a single switch that flips from ‘off’ to ‘on’. Industry and policy sources consistently note that these are separable hurdles: the test needs to be identified correctly, the payer needs criteria for whether it will be covered, and payment levels need to be established through the relevant CMS or commercial mechanisms. Founders who speak fluently about all three are usually much farther along than founders who than founders who treat the code as a later formality. [1] The same principle applies beyond diagnostics. A company selling into providers may live or die based on whether its offering improves a metric tied to penalties, bonuses, risk adjustment, throughput, or labor cost. A company selling to payers may need to fit pharmacy benefits, medical benefits, utilization management rules, or care-management budgets. A company selling to employers may avoid formal reimbursement altogether while still needing a credible ROI argument inside a benefits budget. Different settings, same screen: who pays, from what bucket, and under what mechanism?
This is also why reimbursement readiness is rarely just a commercial issue. It reaches backward into product design. If the company’s evidence plan does not generate the kind of data payers use for decisions, if the product is hard to classify inside existing payment authority, or if the workflow assumptions require uncompensated labor, then reimbursement was not something to be solved later. It was something that should have shaped the product from the beginning.
In rare diseases, the U.S. Orphan Drug Act (ODA) of 1983 is a clean illustration of how policy and reimbursement design can turn a scientific backwater into a core investment thesis. Before the ODA, rare indications (fewer than 200,000 patients in the U.S.) were widely viewed as “therapeutic orphans,” with development costs and regulatory burdens that could not be justified by small addressable markets. The Act rewired those economics by tying orphan designation to a bundle of incentives: a multi‑year period of indication‑specific exclusivity, sizable tax relief on qualified clinical trial spend, and exemptions from user fees that would otherwise reach into the millions. The FDA also pairs designation with grants and regulatory guidance, further decreasing execution risk for smaller, venture‑backed sponsors. [2]
For deal screening, the important insight is that “orphan” is not just a scientific label but a policy‑backed commercial construct. Empirically, ODA‑linked incentives correlate with a sharp increase in rare‑disease pipeline activity, especially in indications that previously attracted little private capital. The Act is widely credited with spurring the development of drugs targeting rare diseases for which no treatment exists. Orphan exclusivity and favorable coverage dynamics mean that many of the highest‑expenditure drugs in Medicare now include at least one orphan designation, underscoring how these policy features translate into premium pricing power and durable cash flows. From a screening standpoint, one of the fastest ways to misjudge a rare‑disease asset is to ignore whether its label strategy, trial design, and pricing logic actually leverage this orphan policy stack.
Digital therapeutics are often discussed as if evidence generation is the main gating factor. Evidence matters, of course, but the category has also exposed how reimbursement strategy can determine whether a clinically validated product reaches scale. A 2024 case study from the Medical Device Innovation Consortium on AppliedVR’s RelieVRx makes this point unusually well. According to the case study, AppliedVR worked with CMS to fit RelieVRx into an existing durable medical equipment benefit category, effectively becoming a first‑mover in using that route for immersive VR therapeutics and accessing payment through existing authority rather than lobbying for a bespoke framework. The authors explicitly frame reimbursement as the combined challenge of coding, coverage, and payment, and highlight how regulatory positioning shaped the reimbursement outcome. [3] That is exactly the kind of story investors should pay attention to. The company did not merely produce a therapy and then hope the system invented a payment path out of admiration. It pursued a route that fit within existing authority. In doing so, it turned a category-level reimbursement question into a company-level strategic advantage.
This example matters because it highlights a subtle but essential point: readiness is often about choosing a plausible first payment home, not solving the entire reimbursement future in one move. Founders regularly talk as if success requires a bespoke code, a novel benefit category, or a perfect top-down policy framework. Sometimes it does. More often, the smarter question is whether the company can enter through an existing mechanism, build evidence and utilization, and widen the aperture later. The AppliedVR case also illustrates why regulatory and reimbursement strategy are linked. The way a product is defined and positioned influences how it can be coded, covered, and paid for. That sounds obvious, but plenty of companies separate these conversations organizationally and mentally, only to realize later that a regulatory choice made the payment path harder or narrower than it needed to be.
One reason investors sometimes avoid pushing on these topics is the fear of being unfairly demanding too early. That instinct is understandable but often misplaced. Seed companies should not be expected to have a complete coding dossier, formal payer coverage, or perfectly de-risked regulatory interactions. They should be expected to have a coherent hypothesis. A founder at this stage should know the likely classification, understand what claims trigger what burdens, identify a probable buyer and payment route, and have a clear view of what must be learned next.
By Series A and beyond, expectations rise. At that point, the company should usually have more than elegant hypotheses. There should be evidence of actual learning behavior: regulatory feedback, narrower intended use, piloting conversations, reimbursement precedent mapping, or pilot economics grounded in real stakeholder conversations. The exact bar varies by subsector, but the principle does not. As the company matures, path knowledge should move from conceptual to operational.
What should not change with stage is the need for coherence. A young company can be forgiven for having unanswered questions. It should not be forgiven for having unasked questions.
This is where the founder’s tone tells you a lot. Strong teams are rarely defensive when pushed on these issues. They may not know everything, but they usually appreciate the relevance of the questions because they have already felt the constraints in product design and planning. Weak teams often signal immaturity not by being wrong, but by being surprised that you asked.
This series is not about building bloated rubrics, so the screening section here can stay small.
In a first pass, three questions usually do most of the work.
What is the most plausible regulatory path for the product as currently described, and what milestone does this round fund?
Who is the economic buyer, and what is the most plausible way money flows for the first real use case?
What has the team already done to pressure-test both assumptions with people who operate inside the regulatory and reimbursement systems?
These questions are enough to surface most of the serious issues, regardless of stage. If a company cannot answer those questions with specificity, it does not yet have a path worth financing.
The practical power of screening for regulatory & reimbursement strategy is that it improves judgment far beyond the regulatory and reimbursement sections of the memo. First, it changes how a commercialization plan is interpreted, since a go-to-market strategy built on a reimbursement mechanism that does not exist is not realistic. Second, it changes how team quality is interpreted, because a team that deeply understands the constraints of coverage, coding, trial design, and purchasing is often far stronger than a superficially more pedigreed team that treats those constraints as someone else’s problem. These domain-specific insights often distinguish robust Founder-Problem Fit (explored in part 4 of this series). Lastly, it changes how product quality is interpreted. Sometimes the product with less technical novelty but a cleaner, shorter, more financeable path is the better venture bet. Market‑access literature in diagnostics and digital health consistently shows that success depends on an early, precise value story that can withstand the friction of coding, coverage, and payment decisions, not just on traditional measures of validity or efficacy. In these categories, founders do not just need evidence that the product works. They need evidence that the system can metabolize it. Many healthcare products fail not because they lack merit, but because the system cannot metabolize them at the speed, cost, or workflow burden the company requires. Regulatory and reimbursement readiness are early signals of metabolic fit.
Once a company has a credible timing story and a coherent regulatory and reimbursement path, the next question gets sharper: what evidence supports the claims, and what kind of traction is real versus decorative? That is where the next article in this series will go. Evidence and traction quality sound obvious until you realize how often healthcare investors are shown activity instead of proof. Pilots with no budget owner, clinical data with unclear comparators, revenue that says little about repeatability, and partnerships that function more as social proof than commercial engine all fall into the ‘activity without proof’ bucket. Regulatory and reimbursement readiness set the stage for that conversation because they tell you what kind of evidence should matter and which traction signals are meaningful. If the path runs through payer coverage, certain economic or outcomes data matter more. If the path depends on clinical adoption, workflow evidence may matter as much as efficacy. If the path is a diagnostic reimbursement story, validity alone will not carry the day.
Thanks for reading Thinking Kat! If you found this issue valuable, please pass it to someone else who would benefit.
[1] Boston Consulting Group. (2023, November 2). Bringing advanced diagnostics to market. https://www.bcg.com/publications/2023/bringing-advanced-diagnostic-testing-to-market
[2] U.S. Food and Drug Administration. (2024, December 7). Designating an orphan product: Drugs and biological products. U.S. Department of Health and Human Services. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
[3] Medical Device Innovation Consortium. (2024, October 9). Case study: Innovative reimbursement strategy for digital therapeutics. https://mdic.org/resources/case-study-innovative-reimbursement-strategy-for-digital-therapeutics/
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.